LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the fourth quarter and year ended December 31, 2015 and provided an update on its product pipeline and corporate activities.
“During the past year, there has been significant progress across our diversified portfolio of deuterium-modified drug candidates. Concert’s resources are focused on rapidly developing our proprietary pipeline, most notably CTP-656 as a once-daily potentiator for treating cystic fibrosis,” said Roger Tung, Ph.D. President and Chief Executive Officer of Concert Pharmaceuticals. “Within our collaborations, we are pleased to see continued progress by Avanir Pharmaceuticals with AVP-786, which is advancing in multiple Phase 2 and Phase 3 studies for major neurologic and psychiatric diseases that represent blockbuster market opportunities.”
